Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

The physiology of amylin and insulin: maintaining the balance between glucose secretion and glucose uptake.

Martin C.

Diabetes Educ. 2006 May-Jun;32 Suppl 3:101S-104S. Erratum in: Diabetes Educ. 2006 Sep-Oct;32(5):798.

PMID:
16751350
2.

New insights into glucose regulation.

Kruger DF, Martin CL, Sadler CE.

Diabetes Educ. 2006 Mar-Apr;32(2):221-8.

PMID:
16554425
3.

Inhibition of glucagon secretion.

Young A.

Adv Pharmacol. 2005;52:151-71. Review.

PMID:
16492545
4.

Clinical implications of amylin and amylin deficiency.

Kruger DF, Gatcomb PM, Owen SK.

Diabetes Educ. 1999 May-Jun;25(3):389-97; quiz 398. Review.

PMID:
10531859
5.

[Amylin--a partner hormone to insulin].

Ascić-Buturović B, Surković I, Heljic B.

Med Arh. 2003;57(3):177-8. Review. Croatian.

PMID:
12858660
6.

Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Woods SC, Lutz TA, Geary N, Langhans W.

Philos Trans R Soc Lond B Biol Sci. 2006 Jul 29;361(1471):1219-35. Review.

7.

The role of amylin in the physiology of glycemic control.

Scherbaum WA.

Exp Clin Endocrinol Diabetes. 1998;106(2):97-102. Review.

PMID:
9628238
8.

Amylin: history and overview.

Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G.

Diabet Med. 1997 Jun;14 Suppl 2:S9-13. Review.

PMID:
9212323
9.

Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus.

Nyholm B, Brock B, Ørskov L, Schmitz O.

Expert Opin Investig Drugs. 2001 Sep;10(9):1641-52. Review.

PMID:
11772274
10.

Optimizing diabetes treatment using an amylin analogue.

Edelman SV.

Diabetes Educ. 2008 Jan-Feb;34 Suppl 1:4S-10S. doi: 10.1177/0145721707313939.

PMID:
18268000
11.
12.

Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study.

Jørgensen JO, Rosenfalck AM, Fisker S, Nyholm B, Fineman MS, Schmitz O, Madsbad S, Holst JJ, Christiansen JS.

Eur J Endocrinol. 2000 Nov;143(5):593-9.

13.

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.

Weyer C, Maggs DG, Young AA, Kolterman OG.

Curr Pharm Des. 2001 Sep;7(14):1353-73. Review. Erratum in: Curr Pharm Des 2001 Dec;7(18):1967.

PMID:
11472273
14.

[Role of amylin in glucose homeostasis and its perspective use in diabetes management].

Otto-Buczkowska E, Mazur-Dworzecka U, Dworzecki T.

Przegl Lek. 2008;65(3):135-9. Review. Polish.

PMID:
18624122
15.

Amylin replacement therapy in patients with type 1 diabetes.

Edelman SV, Caballero L.

Diabetes Educ. 2006 May-Jun;32 Suppl 3:119S-127S.

PMID:
16751353
16.

Amylin agonists: a novel approach in the treatment of diabetes.

Schmitz O, Brock B, Rungby J.

Diabetes. 2004 Dec;53 Suppl 3:S233-8. Review.

17.

Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.

Baron AD, Kim D, Weyer C.

Curr Drug Targets Immune Endocr Metabol Disord. 2002 Apr;2(1):63-82. Review.

PMID:
12477297
18.

The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.

Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW.

Diabetes. 2005 Apr;54(4):1100-7.

19.

Effects of amylin and the amylin agonist pramlintide on glucose metabolism.

Schmitz O, Nyholm B, Orskov L, Gravholt C, Møller N.

Diabet Med. 1997 Jun;14 Suppl 2:S19-23. Review.

PMID:
9212325
20.

[Amylin/IAPP (islet amyloid polypeptide)--physiology and clinical significance].

Ludvik B.

Wien Klin Wochenschr. 1997 Jun 6;109(11):379-83. Review. German.

PMID:
9281227
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk